Screener
Acadia Pharmaceuticals ACAD Gain Loss On Sale Of Other Assets
Gain Loss On Sale Of Other Assets at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Acadia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:GainLossOnSaleOfOtherAssets.
The source filing: Acadia Pharmaceuticals’s 10-K, filed February 26, 2026.
- Filed
- Feb 25, 2026, 7:00 PM EST
- Fiscal year
- FY2025
- Accession
- 0001193125-26-072519
| Line item | Years Ended December 31, 2025 | Years Ended December 31, 2024 | Years Ended December 31, 2023 |
|---|---|---|---|
| Stock-based compensation | 52,135 | 67,049 | 66,421 |
| Amortization of premiums and accretion of discounts on investment securities | (5,424) | (9,304) | (7,533) |
| Amortization of intangible assets | 10,889 | 14,963 | 4,093 |
| Gain on sale of non-financial asset | — | (146,515) | — |
| Gain on strategic investment | — | — | (5,109) |
| Depreciation | 871 | 920 | 1,459 |
| Loss on sale of investment securities | — | — | 524 |
| Deferred income taxes (including benefit from valuation allowance) | (249,879) | — | — |
Item 16. Form 10-K Summary
FAQ
- What is Acadia Pharmaceuticals's gain loss on sale of other assets?
- Acadia Pharmaceuticals (ACAD) reported gain loss on sale of other assets of $0 in Q4 2025.
- How has Acadia Pharmaceuticals's gain loss on sale of other assets changed year-over-year?
- Acadia Pharmaceuticals's gain loss on sale of other assets decreased by 100.0% year-over-year, from $36.63M to $0.
- What does gain loss on sale of other assets mean?
- Gain Loss On Sale Of Other Assets
Ask your AI about Acadia Pharmaceuticals's gain loss on sale of other assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude